Hemostemix Inc (TSE:HEM)
:HEM
Top Page
Hemostemix
(HEM)
Select Model
Select Model
Rating:44Neutral
Price Target:
C$0.09
▲(8.75% Upside)
Action:ReiteratedDate:01/21/26
The score is weighed down primarily by very weak financial performance (no revenue, ongoing losses, rising recent cash burn, and negative equity/solvency risk). Technicals add modest support from short-term trend strength, but valuation remains unattractive/unclear due to negative earnings and no dividend.
Positive Factors
Funding for Product Development
The recent funding will enhance Hemostemix's ability to advance its stem cell therapeutics platform, supporting long-term product development and commercialization efforts.
Negative Factors
Lack of Revenue Generation
The absence of revenue generation highlights significant challenges in achieving profitability, necessitating strategic realignment for financial sustainability.
Read all positive and negative factors
Positive Factors
Negative Factors
Funding for Product Development
The recent funding will enhance Hemostemix's ability to advance its stem cell therapeutics platform, supporting long-term product development and commercialization efforts.
Read all positive factors
Hemostemix (HEM) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$13.67M
Dividend YieldN/A
Average Volume (3M)138.35K
Price to Earnings (P/E)―
Beta (1Y)0.59
Revenue GrowthN/A
EPS Growth-24.89%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding195,253,390
10 Day Avg. Volume155,944
30 Day Avg. Volume138,348
Financial Highlights & Ratios
PEG Ratio0.47
Price to Book (P/B)-1.58
Price to Sales (P/S)0.00
P/FCF Ratio-6.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Hemostemix Business Overview & Revenue Model
Company Description
Hemostemix Inc., a biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source ...
How the Company Makes Money
Hemostemix makes money primarily through the development, licensing, and commercialization of its stem cell therapies. Its key revenue streams include potential licensing agreements with pharmaceutical companies, research grants, and partnerships ...
Hemostemix Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
7
Very Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -60.00 | -100.00 | -223.00 | -495.00 | -1.10K | -2.45K |
| EBITDA | -3.40M | -1.98M | -1.95M | -4.39M | -6.45M | -7.65M |
| Net Income | -4.39M | -2.62M | -2.50M | -5.24M | -6.29M | -7.77M |
Balance Sheet | ||||||
| Total Assets | 1.34M | 991.86K | 313.76K | 465.35K | 563.05K | 2.32M |
| Cash, Cash Equivalents and Short-Term Investments | 1.30M | 705.70K | 155.42K | 135.75K | 219.44K | 257.95K |
| Total Debt | 3.44M | 4.94M | 4.32M | 4.13M | 1.48M | 175.00K |
| Total Liabilities | 4.80M | 8.20M | 7.68M | 7.23M | 5.85M | 3.42M |
| Stockholders Equity | -3.46M | -7.20M | -7.37M | -6.77M | -5.28M | -1.10M |
Cash Flow | ||||||
| Free Cash Flow | -5.18M | -1.90M | -1.42M | -6.10M | -3.48M | -5.98M |
| Operating Cash Flow | -5.18M | -1.90M | -1.42M | -6.10M | -3.48M | -5.98M |
| Investing Cash Flow | -145.58K | 0.00 | 0.00 | 0.00 | 171.12K | 0.00 |
| Financing Cash Flow | 6.42M | 2.45M | 1.44M | 6.02M | 3.27M | 6.21M |
Hemostemix Technical Analysis
Negative
0.08
Price Trends
0.08
Negative
0.08
Negative
0.10
Negative
Market Momentum
>-0.01
Positive
40.63
Neutral
30.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:HEM, the sentiment is Negative. The current price of 0.08 is above the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.08, and below the 200-day MA of 0.10, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 40.63 is Neutral, neither overbought nor oversold. The STOCH value of 30.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:HEM.
Hemostemix Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | C$14.60M | 0.30 | ― | ― | -3.93% | -575.24% | |
44 Neutral | C$13.67M | -7.36 | ― | ― | ― | -24.89% | |
42 Neutral | C$11.74M | -5.25 | 21.59% | ― | ― | -120.00% | |
41 Neutral | C$2.30M | -22.65 | ― | ― | ― | 9.06% |
* Healthcare Sector Average
TSE:HEM
Hemostemix
0.07
-0.02
-22.22%
TSE:IOT
Innovotech
0.17
0.02
13.33%
TSE:BLAB
Britannia Life Sciences Inc
0.09
0.02
28.57%
TSE:SBM.H
Sirona Biochem
0.06
0.00
0.00%
TSE:PREV
PreveCeutical Medical
0.02
>-0.01
-20.00%
TSE:GLAB
Gemina Laboratories Ltd.
0.03
-1.21
-97.58%
Hemostemix Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Hemostemix Raises C$480,000 to Advance Stem Cell Therapy Commercialization
Positive
Jan 1, 2026
Hemostemix has raised C$480,000 through a non-brokered private placement of 4,000,000 common shares priced at C$0.12 each, with the financing subject to final approval from the TSX Venture Exchange and subject to a statutory hold period under secu...
Business Operations and StrategyExecutive/Board Changes
Hemostemix Grants Stock Options to Boost Growth
Positive
Dec 11, 2025
Hemostemix Inc. announced the granting of 963,000 stock options to its directors, officers, employees, and consultants as part of its stock option plan. The options, which have an exercise price of $0.09 per share and expire in 2030, aim to align ...
Private Placements and FinancingProduct-Related Announcements
Hemostemix Highlights VesCell Success at DFCon 2025 and Secures New Funding
Positive
Dec 3, 2025
Hemostemix announced its participation in DFCon 2025, a leading conference on diabetic foot care, where it will showcase its stem cell therapy, VesCell, which has shown promising results in reducing mortality and preserving limbs in diabetic patie...
Business Operations and StrategyPrivate Placements and Financing
Hemostemix Secures CDN$280,594 Private Placement for Operational Growth
Positive
Nov 18, 2025
Hemostemix Inc. announced the conditional approval of its CDN$280,594 private placement by the TSX Venture Exchange, involving the issuance of 2,244,752 common shares. The funds will be used for general working capital, supporting operational expe...
Business Operations and StrategyPrivate Placements and Financing
Hemostemix Closes $461,230 Private Placement to Boost Operations
Neutral
Nov 4, 2025
Hemostemix Inc. announced the closing of its first tranche of a non-brokered private placement, raising $461,230 through the issuance of 4,193,000 units. Each unit consists of a common share and a warrant, with proceeds intended for general workin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.